856676-33-0

Basic information

• Product Name: 8S-Cabergoline
• Synonyms: 8S-Cabergoline;(6aR,9S,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS NO: 856676-33-0
• Molecular Formula: C26H36N5O2
• Molecular Weight: 450.59634
• Product Categories: Neurochemicals, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 856676-33-0.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, Methanol
• Stability: Not stable in methanol solution
• CAS DataBase Reference: 8S-Cabergoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8S-Cabergoline(856676-33-0)
• EPA Substance Registry System: 8S-Cabergoline(856676-33-0)

Safety Data

• Hazardous Substances Data: 856676-33-0(Hazardous Substances Data)

Usage

Uses

8S-Cabergoline is the S-isomer of Cabergoline (C050000), a dopamine D2-receptor agonist.

Upstream product

• 153415-36-2 6-Norcabergoline 
• 591-87-7 Allyl acetate 
• 85329-86-8 (6aR,9R,10aR)-7-allyl-N-[3-(dimethylamino)propyl]-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide 
• 109-90-0 ethyl isocyanate 
• 1892-57-5 N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
• 81409-74-7 (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid 
• 909724-71-6 C₃₂H₅₁N₅O₂Si 
• 474397-68-7 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl](phenoxycarbonyl)amino]carbonyl]ergoline-1-carboxylate 
• 474397-67-6 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl]amino]carbonyl]ergoline-1-carboxylate 
• 109-55-7 1-amino-3-(dimethylamino)propane 
• 72821-79-5 methyl (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylate 
• 474397-69-8 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl][(ethylamino)carbonyl]amino]carbonyl]ergoline-1-carboxylate 
• 25952-53-8 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride 

Relevant articles and documents

New crystal form of cabergoline

The present invention relates to a new needle-form crystalline cabergoline form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and its use in pharmaceutical composition.

PROCESS FOR THE PREPARATION OF AMORPHOUS CABERGOLINE

The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.

Production of Cabergoline and Novel Polymorphic Form Thereof

The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.